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A B S T R A C T
Background: Estimated glomerular ﬁltration rates (eGFRs) at baseline are useful to determine the
severity of renal function and to predict cardiac events. However, no studies aimed to demonstrate
signiﬁcance of eGFRs measured during follow-up and usefulness of combination with nuclear cardiology
for prediction of cardiac death in patients with coronary artery disease (CAD).
Methods: We retrospectively investigated 1739 patients with known/suspected CAD who underwent
myocardial perfusion single photon emission computed tomography (SPECT), who had eGFRs measured
at baseline and after one year and who underwent a three-year follow-up. The SPECT images were
analyzed with the visual scoring model to estimate summed defect scores. Reduction in eGFRs (DeGFR)
was deﬁned as the difference between eGFRs measured after one year and at baseline. The endpoint of
the follow-up was cardiac deaths within three years after the SPECT, which were identiﬁed with medical
records or responses to posted questionnaires.
Results: Cardiac death was observed in 54 of 1739 patients during the follow-up period (45.6 
9.1 months). The multivariate Cox regression analysis showed baseline eGFRs, DeGFR, and summed stress
scores to be signiﬁcant independent variables for prediction of cardiac death. The area under receiver operating
characteristic curves for detection of cardiac death was 0.677 for the baseline eGFR and 0.802 for the follow-up
eGFR. Sensitivity of detection of cardiac death was signiﬁcantly higher in the follow-up eGFR than in the baseline
eGFR (p = 0.0002). Combination of the best cut-off values, i.e. 9 for the summed stress scores and 10 for the
DeGFR, which were suggested by receiver operating characteristic analysis, was useful for risk stratiﬁcation of
cardiac death both in patients with and without chronic kidney disease.
Conclusion: Baseline and follow-up eGFRs as well as nuclear variables are useful to predict cardiac death
in patients with known/suspected CAD.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Prediction of cardiac death is clinically signiﬁcant in patients
with chronic kidney disease (CKD) because cardiovascular disease
is the leading cause of death among patients with CKD before
starting hemodialysis therapy [1]. Myocardial perfusion single
photon emission computed tomography (SPECT) has commonly
been employed to predict cardiac events in patients with coronary* Corresponding author at: Department of Cardiology, Nihon University School of
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[2–4]. In Japan, the multicentre prospective Japanese Assessment
of Cardiac Events and Survival Study (J-ACCESS) has been
conducted since 2001 to evaluate the prognostic value of stress
myocardial perfusion SPECT in patients with suspected or conﬁrmed
CAD [5–8].
There are several studies demonstrating the prognostic value of
myocardial perfusion SPECT for future cardiac events in CKD
patients. The incidences of cardiac death, all-cause mortality, and
non-fatal myocardial infarction (MI) were reported to be higher in
patients with than without CKD who had known or suspected
cardiovascular disease in a nuclear cardiology study [9]. Summed
stress scores (SSS) derived from the SPECT image are considered to
be a reliable predictor of cardiac events among 820 patients with reserved.
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left ventricular ejection fraction (LVEF), and estimated glomerular
ﬁltration rates (eGFRs) have been shown to be independent
predictors of cardiac events in CKD patients in a one-year interim
report of the J-ACCESS 3 [8]. We also have demonstrated that
nuclear variables derived from myocardial perfusion SPECT and
eGFRs are useful for predicting cardiac events and survival in
2243 patients at all stages of CKD including those on hemodialysis
[11].
In those studies, eGFRs measured at baseline were used to
determine the CKD stage and the severity of renal function, and to
predict cardiac events. However, there is no report of studies
demonstrating risk stratiﬁcation of cardiac events and prediction
of cardiac death by means of combination of eGFR reduction and
nuclear cardiology. In addition, no Japanese large-scale nuclear
cardiology studies referred to cardiac death as the primary
endpoint.
We conducted a retrospective large-scale cohort study to
evaluate signiﬁcance of eGFR reduction during a follow-up for
prediction of cardiac death in patients with known or suspected
CAD.
Materials and methods
The institutional review board of Nihon University Itabashi
Hospital approved this study, which proceeded in accordance with
the ethical standards established in the 1964 Declaration of
Helsinki. All study participants provided written informed consent
prior to inclusion in this study.
Patient population
We retrospectively investigated 1739 patients with known or
suspected CAD who underwent rest 201Tl and stress 99mTc-
tetrofosmin myocardial perfusion SPECT [11–16] at Nihon
University Itabashi Hospital between October 2004 and October
2010, who had eGFRs measured at baseline and after approxi-
mately one year, and who underwent a three-year follow-up after
the SPECT. We excluded patients aged 20 years, those who
developed acute MI or unstable angina pectoris within three
months prior to the SPECT, those on hemodialysis, those with
hypertrophic or dilated cardiomyopathy, serious valvular heart
disease or heart failure with class III or higher New York Heart
Association functional classiﬁcation, those who underwent revas-
cularization within 90 days of the SPECT, and those who had no
data on the follow-up eGFR after one year. Patients were diagnosed
as having hypertension if having systolic pressure 140 mmHg
and/or diastolic pressure 90 mmHg within the past three months
or currently under medication to lower blood pressure; as having
diabetes mellitus if having a fasting blood glucose 126 mg/dL,
casual blood glucose 200 mg/dL within the past three months, or
under medication to control hyperglycemia, or already diagnosed
with diabetes mellitus; as having hyperlipidemia if having low-
density lipoprotein cholesterol 140 mg/dL within the past three
months or currently under medication to normalize hypercholes-
terolemia.
Evaluation of eGFRs
The GFR was calculated from serum creatinine levels at the time
of SPECT for each patient in the ﬁnal prognostic analysis population
using the Modiﬁcation of Diet in Renal Disease Equation for
Japanese Patients proposed by the Japanese Society of Nephrology
[17] as follows:
eGFR ¼ A  194  ðSerum CreatinineÞ1:094  ðAgeÞ0:287;where A is 1 for men and 0.739 for women and eGFRs are expressed
as mL/min/1.73 m2.
Patients having baseline eGFRs < 60 mL/min/1.73 m2 were
diagnosed as having CKD. Reduction in eGFR (DeGFR) was deﬁned
as the difference between the eGFR measured in the follow-up
period (follow-up eGFR) and the baseline eGFR. The follow-up
eGFR was measured at 12.0  2.4 months after the baseline.
Electrocardiogram-gated dual-isotope myocardial perfusion SPECT
The procedure of rest 201Tl and stress 99mTc-tetrofosmin
electrocardiogram (ECG)-gated myocardial perfusion SPECT were
performed as a protocol previously reported [11–16]. All patients
received an intravenous (i.v.) injection of 201Tl (111 MBq) and 16-
frame gated SPECT image was initiated 10 min after injection
during rest. Then an i.v. injection of 99mTc-tetrofosmin (740 MBq)
was performed under stress induced by ergometer exercise in
27.5% of the patients or by adenosine triphosphate in 72.5% of
them. Sixteen-frame gated SPECT image was initiated 30 min after
exercise or 30–60 min after adenosine stress. No attenuation or
scatter correction was used. Twelve-lead ECG was monitored
continuously during stress tests. Heart rate and blood pressure
were recorded at baseline and every minute for at least 3 min after
stress.
The projection data over 3608 were obtained with 64  64
matrices and a circular orbit. A triple-detector SPECT system
equipped with low-energy high-resolution collimators was used
(Toshiba, GCA9300A, Tokyo, Japan). SPECT images were recon-
structed from the data with a data processor (Philips North America,
JETStream Workspace 3.0, Andover, MA, USA) combined with
a Butterworth ﬁlter of 201Tl (order 5; cut-off frequency 0.42
cycles/cm), and also that of 99mTc (order 5; cut-off frequency
0.44 cycles/cm), and a ramp ﬁlter.
SPECT image interpretation
The SPECT images were divided into 20 segments [12] on three
short-axis (distal, mid, basal) and one vertical long-axis (mid)
slices, and the tracer uptake of each segment was visually scored
using a 5-point scale (normal, slight, moderate, and severe
reduction of uptake, 0, 1, 2 and 3, respectively; absent uptake,
4) [18]. The sum total of the scores of 20 segments in the stress and
rest images provided the SSS and the summed rest score (SRS),
respectively. The summed difference score (SDS) was calculated as
the difference between the SSS and SRS. Cohen’s kappa (k), which
was calculated to determine the inter-observer variability for the
perfusion score, was 0.92, indicating very good reproducibility.
Sixteen-frame quantitative gated SPECT data were analyzed
using QGSTM software (Cedars-Sinai Medical Center, Los Angeles,
CA, USA) to calculate LVEF (%), end-diastolic volume (LVEDV, mL)
and end-systolic volume (LVESV, mL) as described by Germano
et al. [19].
Patient follow-up
All patients were followed up for approximately three years
(45.6  9.1 months) after the myocardial perfusion SPECT. The study
endpoint was cardiac death deﬁned as death due to any cardiac cause
including fatal MI, sudden arrhythmic death, and congestive heart
failure; identiﬁed with medical records or responses to a posted
questionnaire within the follow-up period.
Statistical analysis
Continuous variables were calculated as means and standard
deviations. Intergroup comparisons of continuous and categorical
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respectively. One-way analysis of variance (ANOVA) followed by
Bonferroni’s multiple comparison test was used for comparison of
data between three groups or more. Univariate analyses proceeded
using a Cox proportional hazards model. Multivariate analyses
proceeded using a stepwise Cox proportional hazards model.
Receiver operating characteristic (ROC) analysis was employed to
determine a cut-off point of parameters for prognostic prediction.
Event-free curves generated with the Kaplan–Meier method were
compared between groups with the log-rank test. All data were
analyzed using MedCalc Software Version 13.1.2.0 (Mariakerke,
Belgium). A p-value of <0.05 was considered statistically
signiﬁcant.
Results
Cardiac death rates and clinical baseline characteristics of patients
The age of 1739 patients who were followed up was
68.4  10.1 years, and 1174 (67.5%) were male and 565 (32.5%)
were female. Cardiac death was observed in 54 of 1739 (3.1%)
patients, consisting of 13 due to fatal MI, 16 due to sudden arrhythmic
death, and 25 due to congestive heart failure.
Table 1 summarizes the baseline characteristics of the patients
with and without cardiac death. The patients with cardiac death
were signiﬁcantly older than those without cardiac death
(p = 0.0012). The proportions (%) of patients who had a historyTable 1
Characteristics of patients with and without cardiac death.
Cardiac
death (+)
Cardiac
death ()
p-value
N = 54 N = 1685
Male patients 40 (74%) 1134 (67%) 0.3688
Age 73  11 68  10 0.0012
Typical chest pain 7 (13%) 96 (6%) 0.0532
History of MI 21 (39%) 389 (23%) 0.0114
History of CAG before SPECT 24 (44%) 630 (37%) 0.3623
History of CAG after SPECT 17 (31%) 320 (19%) 0.0348
History of revascularization 18 (33%) 564 (33%) 0.9003
Hypertension 42 (78%) 1204 (71%) 0.3889
Diabetes mellitus 22 (41%) 533 (32%) 0.2058
Hyperlipidemia 16 (30%) 797 (47%) 0.0154
Smoking 12 (22%) 424 (25%) 0.7404
Aspirin 32 (59%) 846 (50%) 0.2415
Statins 10 (19%) 568 (34%) 0.0288
b-Blockers 18 (33%) 332 (20%) 0.0222
Ca-antagonists 25 (46%) 820 (49%) 0.8380
Nitrates 18 (33%) 436 (26%) 0.2842
ARB 27 (50%) 662 (39%) 0.1490
ACE 7 (13%) 154 (9%) 0.4742
SSS 16.1  13.4 4.9  8.6 <0.0001
SRS 11.2  11.8 3.1  7.3 <0.0001
SDS 4.9  5.9 1.8  3.7 <0.0001
Rest LVEF 48.3  20.2 62.6  14.2 <0.0001
Rest LVEDV 114.9  64.5 80.2  39.4 <0.0001
Rest LVESV 70.4  61.3 34.3  33.2 <0.0001
Stress LVEF 47.4  19.7 62.2  14.6 <0.0001
Stress LVEDV 135.0  74.9 91.3  42.5 <0.0001
Stress LVESV 83.2  71.7 39.5  36.9 <0.0001
Baseline eGFR 54.3  24.8 67.4  21.1 <0.0001
Follow-up eGFR 38.2  23.4 64.0  20.4 <0.0001
DeGFR 16.2  22.1 3.4  15.3 <0.0001
Hemoglobin 12.3  2.4 13.4  1.7 <0.0001
MI, myocardial infarction; CAG, coronary angiography; SPECT, single photon
emission computed tomography; ARB, angiotensin receptor blockers; ACE,
angiotensin-converting enzyme inhibitors; SSS, summed stress score; SRS,
summed rest score; SDS, summed difference score; LVEF, left ventricular
ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left
ventricular end-systolic volume; eGFR, estimated glomerular ﬁltration rate;
DeGFR, reduction in eGFR.of MI and who underwent coronary angiography (CAG) after the
SPECT were signiﬁcantly higher in the group with than without
cardiac death (p = 0.0114 and 0.0348, respectively). On the other
hand, the proportions of patients who had hyperlipidemia and who
underwent statin treatment were signiﬁcantly lower in the group
with than without cardiac death (p = 0.0154 and 0.0288, respec-
tively). However, there were no signiﬁcant differences in the
proportions of patients stratiﬁed by typical chest pain, a history of
CAG before the SPECT, a history of revascularization, hypertension,
diabetes mellitus, smoking habit, or medication except statins
(aspirin, b-blockers, Ca-antagonists, nitrates, angiotensin receptor
blockers, and angiotensin-converting enzyme inhibitors) between
the two groups. Summed defect scores (SSS, SRS and SDS) as well as
QGS parameters of LVEDV and LVESV in both rest and stress images
were signiﬁcantly higher in the group with than without cardiac
death (both p < 0.0001). In contrast, LVEF in both rest and stress
images, the baseline eGFR, the follow-up eGFR, and hemoglobin
were signiﬁcantly lower in the group with than without cardiac
death (all p < 0.0001). The mean DeGFR in the group with cardiac
death was signiﬁcantly larger than that in the group without
cardiac death (16.2 mL/min/1.73 m2 vs. 3.4 mL/min/1.73 m2;
p < 0.0001).
Data on glycated hemoglobin A1c were obtained from 87%
(1516/1739) of the patients. Glycated hemoglobin A1c was
6.6  1.3% (n = 52) and 6.4  1.1% (n = 1464) in the patients with
and without cardiac death, respectively, and was not signiﬁcantly
different between the two groups (p = 0.1434).
Angiographic CAD prior to SPECT
Table 2 summarizes the severity of angiographic CAD prior to
the SPECT in the patients with and without cardiac death. CAG was
performed in 654 of 1739 patients prior to the SPECT, and of those,
24 patients experienced cardiac death. The severity of CAD in
patients with cardiac death was similar to that in patients without
cardiac death.
Relationship between SSS and baseline eGFR
Fig. 1 illustrates the SSS in subgroups with the baseline eGFR
60 mL/min/1.73 m2, 40–59 mL/min/1.73 m2, and <40 mL/min/
1.73 m2. The mean SSS in the subgroup with the baseline
eGFR < 40 mL/min/1.73 m2 was 7.8, being signiﬁcantly higher
than those in the subgroups with the baseline eGFR 40 to 59 mL/
min/1.73 m2 and 60 mL/min/1.73 m2 (5.7 and 4.8; p = 0.0171 and
0.0001, respectively). A statistically signiﬁcant difference was also
observed between the subgroups with the baseline eGFR 40 to
59 mL/min/1.73 m2 and 60 mL/min/1.73 m2 (p = 0.0472).
Prediction of cardiac death
Table 3 shows the results of the univariate Cox proportional
hazards regression analysis with cardiac death rates as theTable 2
Results of coronary angiography performed in patients prior to single photon
emission computed tomography with and without cardiac death.
Cardiac death (+) Cardiac death () p-value
N = 24 N = 630
Angiographic CAD
0 Vessel 1 (4%) 22 (4%) 0.6977
1 Vessel 9 (38%) 253 (40%) 0.9612
2 Vessels 7 (29%) 170 (27%) 0.9983
3 Vessels 7 (39%) 185 (29%) 0.8537
CAD, coronary artery disease.
Fig. 2. Receiver operating characteristic curves for detection of cardiac death by
measures of baseline and follow-up eGFRs in patients with known or suspected
coronary artery disease.
Area under the curve (AUC) of baseline eGFR: 0.677; AUC of follow-up eGFR: 0.802;
The AUCs were statistically signiﬁcantly different between the baseline and follow-
up eGFRs (p = 0.0002). eGFR, estimated glomerular ﬁltration rate.
Table 4
Multivariate Cox proportional hazards regression analysis.
Hazard ratio 95% Conﬁdence interval p-value
Baseline eGFR 0.9474 0.9341–0.9608 <0.0001
DeGFR 1.0689 1.0532–1.0849 <0.0001
SSS 1.0589 1.0402–1.0778 <0.0001
eGFR, estimated glomerular ﬁltration rate; SSS, summed stress score.
Fig. 1. Summed stress scores stratiﬁed by the baseline estimated glomerular
ﬁltration rate (eGFR) in patients with known or suspected coronary artery disease.
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cardiac death rates were age, typical chest pain, a history of MI,
summed defect scores (SSS, SRS, SDS), LVEF, LVEDV, and LVESV in
the rest and stress images, baseline and follow-up eGFRs, DeGFR,
and hemoglobin.
The multivariate Cox proportional hazards regression model
analysis indicated the baseline eGFR (p < 0.0001), DeGFR
(p < 0.0001), and SSS (p < 0.0001) as signiﬁcant independent
variables for prediction of cardiac death (Table 4).
Detection of cardiac death by measures of baseline and follow-up
eGFRs
Fig. 2 illustrates ROC curves for detection of cardiac death by
measures of baseline and follow-up eGFRs. The area under the ROC
curve was 0.677 for the baseline eGFR and 0.802 for the follow-up
eGFR. Sensitivity of detection of cardiac death was signiﬁcantly
higher in the follow-up eGFR than in the baseline eGFR (p = 0.0002).Table 3
Univariate Cox proportional hazards regression analysis.
Chi-Square Hazar
Age 11.036 1.0
Male patients 1.090 1.3
Typical chest pain 4.744 2.4
History of MI 6.880 2.0
History of revascularization 0.003 0.9
Hypertension 1.027 1.3
Diabetes mellitus 2.053 1.4
Hyperlipidemia 6.555 0.4
Smoking 0.257 0.8
Statin use 5.263 0.4
SSS 66.555 1.0
SRS 49.228 1.0
SDS 31.157 1.1
Rest LVEF 46.953 0.9
Rest LVEDV 36.256 1.0
Rest LVESV 49.320 1.0
Stress LVEF 46.809 0.9
Stress LVEDV 46.980 1.0
Stress LVESV 57.273 1.0
Baseline eGFR 23.998 0.9
Follow-up eGFR 84.741 0.9
DeGFR 33.486 1.0
Hemoglobin 22.713 0.7
MI, myocardial infarction; SSS, summed stress score; SRS, summed rest score; SDS
ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; eGFR,Prediction of cardiac death by combination of SSS and eGFR reduction
in non-CKD and CKD patients
Fig. 3 shows Kaplan–Meier survival curves for non-CKD (a) and
CKD (b) patients stratiﬁed with both cut-off SSS and DeGFR. The
cut-off values were 9 for SSS and 10 for DeGFR, which were the best
values suggested by the ROC analysis. Generally, the non-CKDd ratio 95% Conﬁdence interval p-value
550 1.0224–1.0886 0.0009
830 0.7548–2.5340 0.2964
169 1.0968–5.3258 0.0294
798 1.2067–3.5845 0.0087
828 0.5598–1.7254 0.9520
935 0.7361–2.6381 0.3107
872 0.8666–2.5523 0.1518
662 0.2607–0.8337 0.0105
470 0.4475–1.6035 0.6120
477 0.2261–0.8864 0.0218
773 1.0583–1.0967 <0.0001
693 1.0495–1.0893 <0.0001
199 1.0765–1.1651 <0.0001
513 0.9378–0.9649 <0.0001
116 1.0078–1.0153 <0.0001
135 1.0097–1.0173 <0.0001
503 0.9366–0.9642 <0.0001
117 1.0084–1.0151 <0.0001
131 1.0097–1.0165 <0.0001
660 0.9528–0.9794 <0.0001
375 0.9248–0.9504 <0.0001
149 1.0098–1.0199 <0.0001
151 0.6235–0.8203 <0.0001
, summed difference score; LVEF, left ventricular ejection fraction; LVEDV, left
 estimated glomerular ﬁltration rate.
Fig. 4. Annual cardiac death rates stratiﬁed with DeGFR in subgroups with
SSS < 9 or  9 in non-CKD (a) and CKD (b) patients.
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; SSS,
summed stress score.
Fig. 3. Kaplan–Meier survival curves for non-CKD (a) and CKD (b) patients stratiﬁed
with cut-off SSS and DeGFR.
The cut-off values of SSS and DeGFR were the best values suggested by the receiver
operating characteristic curves analysis, non-CKD patients: eGFR  60 mL/min/
1.73 m2, n = 1139; CKD patients: eGFR < 60 mL/min/1.73 m2, n = 600.
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; SSS,
summed stress score.
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prognosis in comparison with the CKD patients (eGFR < 60 mL/
min/1.73 m2, n = 600). In the non-CKD patients, a subgroup with
SSS  9 and DeGFR  10 (n = 67) had signiﬁcantly higher risk of
cardiac death than other subgroups (p < 0.0001). In the CKD
patients, also a subgroup with SSS  9 and DeGFR  10 (n = 29) had
further signiﬁcantly higher risk of cardiac death than other
subgroups (p < 0.0001) and had the poorest prognosis among all
subgroups studied. In contrast, the most favorable prognosis was
observed in both the non-CKD (n = 671) and CKD (n = 388) patients
with SSS < 9 and DeGFR < 10. Furthermore, in the CKD patients,
similar Kaplan–Meier curves were observed between two sub-
groups with SSS < 9 and DeGFR  10 (n = 50) and with SSS  9 and
DeGFR < 10 (n = 133).
Comparison of annual cardiac death rates in sub-groups divided
with combination of SSS and eGFR reduction in non-CKD and
CKD patients
Fig. 4 shows annual cardiac death rates stratiﬁed with the
DeGFR in subgroups with SSS < 9 or 9 in the non-CKD (a) and
CKD (b) patients. Overall annual cardiac death rates were 0.3% in
the non-CKD patients with SSS < 9, 1.5% in the non-CKD patients
with SSS  9, 0.8% in the CKD patients with SSS < 9, and 5.1% in the
CKD patients with SSS  9.
In the non-CKD patients with SSS < 9, the annual cardiac death
rates were 0.7% in the case of DeGFR  10 (n = 224) and 0.1% in the
case of DeGFR < 10 (n = 671) and signiﬁcantly different between
the two cases (p = 0.0161). In the non-CKD patients with SSS  9,
the annual cardiac death rates were 3.5% in the case of DeGFR  10(n = 67) and 0.8% in the case of DeGFR < 10 (n = 177) and
signiﬁcantly different between the two cases (p = 0.0162).
In the CKD patients with SSS < 9, the annual cardiac death rate
was 2.7% in the case of DeGFR  10 (n = 50) and 0.6% in the case of
DeGFR < 10 (n = 388) and signiﬁcantly different between the two
cases (p = 0.0311). In the CKD patients with SSS  9, the annual
cardiac death rates were 11.5% in the case of DeGFR  10 (n = 29)
and 3.8% in the case of DeGFR < 10 (n = 133) and signiﬁcantly
different between the two cases (p = 0.0044).
Discussion
We conducted this retrospective large-scale cohort study to
evaluate signiﬁcance of reduction in eGFRs at approximately one
year after the baseline for predicting cardiac death in 1739 patients
with known or suspected CAD. The results demonstrated that the
follow-up eGFR has prognostic value to cardiac death superior to
the baseline eGFR and provides precise risk stratiﬁcation of cardiac
death in combination with the SSS. To date, there has been no
report of Japanese large-scale nuclear cardiology studies evaluat-
ing cardiac death as the primary endpoint and predicting cardiac
death with follow-up eGFRs. Therefore, this is the ﬁrst report
indicating the signiﬁcance of follow-up eGFRs for prediction of
cardiac death in patients with known or suspected CAD.
As shown in Fig. 3, the Kaplan–Meier estimation indicated that
the patients with SSS < 9 and DeGFR < 10 had the best prognosis
and the patients with SSS  9 and DeGFR  10 had the poorest
prognosis. The patients with SSS < 9 and DeGFR  10 had similar
survival curves to those of the patients with SSS  9 and
DeGFR < 10; those survival curves were placed between those
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SSS  9 and DeGFR  10. These results were similar between the
CKD and non-CKD patients and the patients with SSS  9 and
DeGFR  10 had higher risk of early cardiac death than the patients
of the other subgroups, irrespective of whether they had CKD.
Therefore, follow-up eGFR measured after one year was more
important for prediction of prognosis in patients with CAD than
baseline eGFRs. The multivariate Cox proportional hazards
regression model analysis also identiﬁed the DeGFR as well as
the baseline eGFR and the SSS as signiﬁcant independent variables
for prediction of cardiac death. Furthermore, the ROC analysis
suggested that the follow-up eGFR had signiﬁcantly higher
sensitivity for detection of cardiac death than the baseline eGFR.
Annual cardiac death rates were reported to be higher in CKD
patients with SSS  8 than in non-CKD patients with SSS  8 in the
previous large-scale study in the USA [9]. In our results, annual death
rates were also higher in CKD patients with the SSS  9 than in non-
CKD patients with the SSS  9 (5.1% vs. 0.8%). In addition, risk
stratiﬁcation with DeGFR provided further information, i.e. the
annual death rates increased to 11.5% in the case of DeGFR  10 but
decreased to 3.8% in the case ofDeGFR < 10 among the CKD patients.
Likewise, the annual death rates in the non-CKD patients also
increased to 3.5% in the case of DeGFR  10 but decreased to 0.8% in
the case of DeGFR < 10. Consequently, assessment of reduction in
eGFRs (DeGFR) as well as baseline eGFRs and SSS provides clinically
signiﬁcant information for prediction of cardiac death and
‘SSS  9 and DeGFR  100 was considered to be an index of poor
prognosis in the short term in patients with known or suspected
CAD.
LVEF is also known to be an important factor for prediction of
cardiac events and has been reported as an independent predictor in
the J-ACCESS studies [5,8]. In the present study, LVEF was nominated
as a signiﬁcant variable by the univariate analysis but not by the
multivariate analysis. This is possibly considered to be results from
changes in the LVEF being concurrent with reduction in the eGFR.
The correlation between the eGFR and the LVEF as well as the causes
of the eGFR reduction should be clariﬁed in a future study.
In patients with chronic heart failure, worsening renal function
is recognized as a predictor of a poor prognosis [20–22]. Sub-
analysis of the RALES (Randomized Aldactone Evaluation Study)
indicated that worsening renal function as well as baseline eGFR is
a signiﬁcant poor prognostic factor in patients with chronic heart
failure and an ejection fraction < 35%. Association of worsening
renal function with poor prognosis is similar to our present results
obtained from patients with known or suspected CAD. Therefore,
worsening renal function is useful for prediction of cardiac events
in not only heart failure patients but also CAD patients.
Worsening renal function should be also considered associated
with contrast-induced nephropathy [23,24]. However, in our
present study, the number of patients having a history of CAG was
654 of 1739 (37.6%) and the number of patients undergoing re-
examination with CAG was 337 (19.4%). During the follow-up,
1403 patients did not receive any doses of contrast agents, and
263 received only one dose and 73 multiple doses of contrast
agents. The DeGFRs were 4.0  15.1 in the no-dose group,
3.2  19.5 in the one-dose group, and 2.2  12.7 in the multiple-
dose group; the frequency of use of contrast agents did not correlate
with the DeGFR (p = 0.513, ANOVA). Therefore, involvement of
contrast-induced nephropathy in worsening renal function was
considered negligible in the present study.
The limitation of this study was that it was a retrospective,
single center investigation. However, the number of patients in our
study was 1739, although it was a single center study, and was
larger than that in important studies on prediction of cardiac
events in CKD patients performed in the USA (n = 1652) [9] and
Japan (n = 529) [7,8].In conclusion, the baseline and follow-up GFRs as well as
nuclear variables are useful for prediction of cardiac death in
patients with known or suspected CAD.
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